Table 5.

Risk of renal events in a 1:1 propensity score-matched cohort of new users of PPI (n=20,270) and new users of H2 blockers (n=20,270)

OutcomeH2 Blockers (n=20,270)PPI (n=20,270)
Incident eGFR<60 ml/min per 1.73 m2Number of events (%)4,429 (21.85)5,204 (25.67)
Incident rate (95% CI)5408.24 (5249.96 to 5567.52)6563.33 (6385.01 to 6741.65)
HR (95% CI)1.01.23 (1.17 to 1.30)
Incident CKDNumber of events (%)2,234 (11.02)2,776 (13.70)
Incident rate (95% CI)2569.86 (2463.30 to 2676.43)3294.88 (3172.31 to 3417.44)
HR (95% CI)1.01.28 (1.18 to 1.38)
Doubling of serum creatinineNumber of events (%)759 (3.74)1,185 (5.85)
Incident rate (95% CI)816.98 (758.86 to 875.10)1300.96 (1226.89 to 1375.03)
HR (95% CI)1.01.63 (1.47 to 1.81)
>30% decline in eGFRNumber of events (%)3,949 (19.48)4,762 (23.49)
Incident rate (95% CI)4533.25 (4391.86 to 4674.64)5669.45 (5508.42 to 5830.47)
HR (95% CI)1.01.32 (1.25 to 1.39)
ESRDNumber of events (%)25 (0.12)38 (0.19)
Incident rate (95% CI)26.50 (16.11 to 36.88)40.69 (27.75 to 53.63)
HR (95% CI)1.01.48 (0.49 to 4.50)
ESRD or >50% decline in eGFRNumber of events (%)947 (4.67)1433 (7.07)
Incident rate (95% CI)1024.27 (959.03 to 1089.51)1582.80 (1500.85 to 1664.75)
HR (95% CI)1.01.59 (1.45 to 1.74)
  • Incident rate as incident per 100,000 person-years.

  • HRs were obtained from Cox models adjusted for baseline eGFR, age, race, sex, diabetes mellitus, hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, gastroesophageal reflux disease, upper GI tract bleeding, ulcer disease, H. pylori infection, Barrett esophagus, achalasia, stricture, and esophageal adenocarcinoma.